Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2017 | Upcoming results from clinical trials for treating relapsed, low grade lymphoma

Nathan Fowler • 9 Dec 2017
ASH 2017
Lymphoma Antibodies Lenalidomide Rituximab

Nathan Fowler, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, talks about the clinical trials with results being released soon for the treatment of low grade lymphoma. Trials include several drugs being combined with lenalidomide, as well as checkpoint inhibitors. Speaking at the 2017 American Society of Hematology (ASH) Annual Meeting, in Atlanta, GA, Dr Fowler describes the potential of CAR T-cell therapy with checkpoint inhibitors, with front-line studies being presented in upcoming meetings.

More from Nathan Fowler

1:36
ELARA: Tisa-cel in follicular lymphoma
Nathan Fowler • 12 Dec 2021
0:39
10 year follow up of rituximab and lenalidomide in low tumor burden FL
Nathan Fowler • 12 Dec 2021
1:03
RELEVANCE: Rituximab and lenalidomide in FL
Nathan Fowler • 12 Dec 2021
3:44
ELARA: tisa-cel in R/R follicular lymphoma
Nathan Fowler • 18 Jun 2021

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals